Company Overview
ZeroStack Corp. operates primarily through its subsidiary, Phatebo GmbH, which engages in the pharmaceutical distribution business within Germany. The company functions across two distinct segments, Commercial & Wholesale and Digital Assets, distributing a range of pharmaceutical goods and medical products to treat various health indications. This operational model places the entity within the Financial Services sector, specifically under the Asset Management industry, where capital allocation and resource management are central to business activities. With a market capitalization of $15.27M, annual revenue of $35.68M, and a workforce of 21 employees, the company represents a small-cap entity with a limited operational footprint. These financial figures indicate that ZeroStack Corp. is a micro-cap stock with minimal revenue generation relative to its sector peers, suggesting a company in a specialized niche market rather than a broad-scale industrial player. The small employee count of 21 further underscores the lean organizational structure typical of firms focused on high-margin distribution or specialized asset management strategies in emerging markets.
Financial Health
The company reported revenue of $35.68M over the trailing twelve months, yet it recorded a net income of $-115,410,000 and an EBITDA of $-11,027,000. The significant gap between positive revenue and substantial negative net income reveals a highly aggressive cost structure where operating expenses far exceed gross profits, erasing all earnings before interest, taxes, and amortization. Free cash flow stands at $-5,176,000, indicating that the company is burning cash rather than generating liquidity, which severely limits its financial flexibility for debt repayment, capital expenditures, or strategic acquisitions without external financing. The gross margin is 4.6%, suggesting thin pricing power or high cost of goods sold in the pharmaceutical distribution model. The operating margin is -54.8%, reflecting severe inefficiencies in core operations or substantial administrative overheads relative to sales. The profit margin is 0.0%, confirming that the company is currently unprofitable on a bottom-line basis. Total cash holdings of $5.60M are significantly outweighed by total debt of $53.93M, creating a net debt position that strains the balance sheet. The debt-to-equity ratio of 76.44 indicates a highly leveraged balance sheet where equity capital is minimal compared to liabilities. The current ratio of 1.01 suggests that the company possesses just enough current assets to cover its current liabilities, leaving little margin for error in short-term liquidity management. Return on equity is -307.5% and return on assets is -9.3%, metrics that reveal management is destroying shareholder value and failing to generate returns on the capital deployed in the business.
Valuation Assessment
The trailing P/E ratio is N/A and the forward P/E is N/A, a situation that implies earnings are currently negative and therefore traditional price-to-earnings multiples cannot be calculated to assess historical or expected earnings trajectory. The price-to-book ratio is 0.09, indicating that the market values the company at less than one-tenth of its book value, which typically suggests significant undervaluation or, conversely, that the assets may be impaired or the business model lacks profitability. The price-to-sales ratio is 0.43, showing that the market price is less than half of the revenue generated, while the EV/EBITDA stands at -5.77, reflecting the negative earnings context. The stock has a 52-week high of $47.00 and a 52-week low of $5.77, placing the current trading range within a wide band of volatility. Assuming a price near the lower end of the typical range for such a distressed profile, the stock trades well below the 52-week high, reflecting significant downside from recent peaks or a prolonged period of underperformance. The beta is 1.96, meaning the stock price is nearly twice as volatile as the broader market, exposing investors to substantial price swings during periods of market turbulence.
Growth & Income
Revenue growth year-over-year is 22.3%, while earnings growth is N/A due to the company's consistent losses, implying that top-line expansion is not yet translating into bottom-line profitability. Since the company does not pay dividends, the dividend yield is N/A and the payout ratio is 0.0%, meaning the entity reinvests its limited earnings or utilizes cash reserves to fund operations rather than distributing income to shareholders. This lack of dividend income is consistent with a firm that must prioritize survival and operational restructuring over returning capital to investors. The overall growth and income profile is characterized by positive top-line expansion coupled with deep losses and no income distribution, presenting a high-risk scenario where revenue growth alone is insufficient to stabilize the financial position. The combination of rising revenue and negative earnings suggests the company is scaling operations, but the scale required to achieve profitability has not yet been reached.